This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. Several health plans in the U.S. will not cover the recently approved Alzheimer’s drug for certain customers, exposing those patients to thousands of dollars in potential costs. Their decision stands in contrast to Medicare. The federal coverage program mainly for people ages 65 and older announced in July 2023 that it will cover Leqembi shortly after regulators gave the drug full approval. (Eisai via AP, File)
Featured Photo Galleries
